Targets › FGFR2
38 programs from 36 companies in 87 trials: 54 Phase 2, 25 Phase 1, 8 Phase 3; Oncology, Gastroenterology, Other; next expected readout Nov 2026.
Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. (UniProt, P21802)
Open in Phaseline: the race on FGFR2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| TransThera Sciences (Nanjing) | TT-00420 (tinengotinib) Fibroblast growth factor receptor (FGFR) inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 3 | Cholangiocarcinoma; Cholangiocarcinoma Metastatic; Breast Cancer; Prostate Cancer (CRPC) | Dec 2026 |
| Exelixis | Zanzalintinib (XL092) Multi-targeted tyrosine kinase inhibitor targeting FGFR, MET, ROS1, and AXL | FGFR1, FGFR2, FGFR3, FGFR4, MET, KIT, PDGFRA | Phase 3 | Non-Clear Cell Renal Cell Carcinoma; Colorectal Cancer; Meningioma; Head and Neck Squamous Cell Carcinoma … | Dec 2026 |
| Johnson & Johnson (Janssen) | Erdafitinib (TAR-210) Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 3 | Urothelial Cancer; Non-Muscle Invasive Bladder Neoplasms; Urothelial Carcinoma; Advanced Malignant Solid Neoplasm … | Dec 2026 |
| Taiho Oncology | Futibatinib (TAS-120) Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 2 | Advanced Cholangiocarcinoma; Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Advanced/Metastatic Cancer; Biliary Tract Neoplasms … | Dec 2026 |
| Beijing InnoCare Pharma Tech | ICP-192 FGFR2 inhibitor | FGFR2 | Phase 2 | Intrahepatic Cholangiocarcinoma (ICC) | Dec 2026 |
| Memorial Sloan Kettering Cancer Center | Palifermin Fibroblast growth factor receptor 2 agonist | FGFR2 | Phase 2 | Leukemia | Dec 2026 |
| Tianjin Medical University Cancer Institute and Hospital | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Gastrointestinal Cancer | Dec 2026 |
| Shanghai Zhongshan Hospital | HRS-4642 FGFR1/2/3/4 inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 2 | Biliary Tract Cancer; Pancreatic Cancer | Dec 2026 |
| Sameek Roychowdhury | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Advanced Pancreatic Carcinoma | Dec 2026 |
| University of Utah | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Mar 2027 |
| UNICANCER | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Solid Tumor, Miscellaneous | Jun 2027 |
| Mehmet Akce | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Intrahepatic Cholangiocarcinoma | Jul 2027 |
| National Cancer Institute (NCI) | Rogaratinib Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 2 | Locally Advanced Gastrointestinal Stromal Tumor | Jul 2027 |
| Elevar Therapeutics | Lirafugratinib FGFR2 inhibitor | FGFR2 | Phase 2 | FGFR2 Gene Fusion/Rearrangement | Sep 2027 |
| Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | bemarituzumab Fibroblast growth factor receptor 2 inhibitor; Low affinity immunoglobulin gamma Fc region receptor III-A binding agent | FGFR2, FCGR3A | Phase 2 | Metastatic Gastro-esophageal Adenocarcinoma | Sep 2027 |
| Kinaset Therapeutics | Frevecitinib (KN-002) FGFR2 inhibitor | FGFR2 | Phase 2 | Severe Asthma | Nov 2027 |
| Ohio State University Comprehensive Cancer Center | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Locally Advanced Ampulla of Vater Carcinoma | Dec 2027 |
| Haitao Zhao, MD | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Biliary Tract Cancer (BTC) | Dec 2027 |
| Lund University Hospital | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Dedifferentiated Liposarcoma | Dec 2027 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Donafenib Multi-kinase inhibitor with activity against FGFRs, VEGFR, and RET | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 2 | Hepatocellular Carcinoma | Jan 2028 |
| National Cancer Center, Japan | E7090 FGFR inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 2 | Advanced or Recurrent Solid Tumors | Mar 2028 |
| Hutchmed | Hmpl-453 (HMPL-453) Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor | FGFR1, FGFR2, FGFR3 | Phase 2 | Advanced Intrahepatic Cholangiocarcinoma | Jun 2028 |
| Dana-Farber Cancer Institute | Pemigatinib (INCB054828) Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | SDH Gene Mutation | Oct 2028 |
| QED Therapeutics, a BridgeBio company | Infigratinib Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 2 | Achondroplasia | Mar 2030 |
| City of Hope Medical Center | Palifermin Fibroblast growth factor receptor 2 agonist | FGFR2 | Phase 2 | Acute Myeloid Leukemia With Complex Karyotype | Nov 2031 |
| Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Derazantinib Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 2 | Intrahepatic Cholangiocarcinoma | – |
| AstraZeneca | Fexagratinib (AZD4547) Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 1 | Muscle Invasive Bladder Cancer; Metastatic Breast Cancer | Nov 2026 |
| BeOne Medicines | BG-C137 anti-FGFR2b antibody-drug conjugate | FGFR2 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| OHSU Knight Cancer Institute | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 1 | Acute Myeloid Leukemia | Dec 2026 |
| Hangzhou Zhongmei Huadong Pharmaceutical | HDM2020 FGFR2b-targeted antibody-drug conjugate | FGFR2 | Phase 1 | Squamous Non-small Cell Lung Cancer(NSCLC); Solid Tumor | Jan 2027 |
| Cogent Biosciences | CGT4859 selective FGFR2/3 inhibitor | FGFR2, FGFR3 | Phase 1 | Intrahepatic Cholangiocarcinoma (Icc) | Mar 2027 |
| Tyra Biosciences | TYRA-200 FGFR 1/2/3 tyrosine kinase inhibitor | FGFR1, FGFR2, FGFR3 | Phase 1 | Locally Advanced Cholangiocarcinoma | Mar 2027 |
| Eisai | E-7090 (E7090) Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor | FGFR1, FGFR2, FGFR3 | Phase 1 | Hepatic Impairment | Aug 2027 |
| KinoTeck Therapeutics | KNT-0916 FGFR2 inhibitor | FGFR2 | Phase 1 | Solid Tumors With FGFR2 Alterations, Adult | Sep 2027 |
| Massachusetts General Hospital | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 1 | Advanced Solid Tumor | Dec 2027 |
| Tyra Biosciences | TYRA-430 FGFR inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 1 | Metastatic Hepatocellular Carcinoma | Jan 2028 |
| M.D. Anderson Cancer Center | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 1 | Advanced Cholangiocarcinoma | Feb 2028 |
| 3H Pharmaceuticals | 3HP-2827 FGFR2 inhibitor | FGFR2 | Phase 1 | Solid Tumors With FGFR2 Alterations, Adult | Jun 2028 |
Non-Muscle Invasive Bladder Neoplasms (3) Advanced Solid Tumor (3) Colorectal Cancer (3) Solid Tumors With FGFR2 Alterations, Adult (2) Hepatocellular Carcinoma (2) Urothelial Cancer (2) Advanced Malignant Solid Neoplasm (2) Solid Tumor (2) Advanced Cholangiocarcinoma (2) Hepatic Impairment (2) Intrahepatic Cholangiocarcinoma (2) Muscle Invasive Bladder Cancer (1)
small molecule (24), mixed (11), antibody (2), protein or peptide (1)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (2) Tyra Biosciences (2) KinoTeck Therapeutics (1) AstraZeneca (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) Johnson & Johnson (Janssen) (1) Hangzhou Zhongmei Huadong Pharmaceutical (1) Taiho Oncology (1) Shanghai Zhongshan Hospital (1) Elevar Therapeutics (1) Massachusetts General Hospital (1) BeOne Medicines (1) Exelixis (1) UNICANCER (1) QED Therapeutics, a BridgeBio company (1) National Cancer Center, Japan (1) National Cancer Institute (NCI) (1) TransThera Sciences (Nanjing) (1) Mehmet Akce (1) Memorial Sloan Kettering Cancer Center (1)
FGFR3 (28) FGFR1 (27) FGFR4 (12) FCGR3A (1) MET (1) KIT (1) PDGFRA (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.